JP5685752B2 - Blood flow promoting agent - Google Patents

Description

The present invention relates to a blood flow promotion improving agent characterized by containing an aqueous component of camellia (Camellia japonica) fruit and / or seed defatted koji belonging to the camellia family, as an active ingredient, and The present invention relates to an oral composition for promoting and / or improving blood flow.

Blood components are composed of cellular components such as red blood cells, white blood cells, and platelets, and liquid components of plasma, and the ratio is said to be 45:55. Each blood component plays an important role in maintaining the homeostasis of the living body. Red blood cells combine with hemoglobin in the cells and oxygen to transport oxygen to the whole body tissue, and white blood cells act for immunity such as phagocytosis and elimination of viruses, microorganisms and foreign substances that have entered from the outside, and platelets aggregate A lump is formed to cover the damaged part and prevent bleeding. In addition, plasma plays a role in nutrients, transport of hormones, carbon dioxide, and waste collection.

In recent years, blood flow has decreased due to aging, stress, smoking, westernization of diet, lack of exercise, external environment, etc., and the number of people complaining of various physical condition is increasing. Reduced blood flow is known to cause various symptoms such as arteriosclerosis, hypertension, decreased immunity, alopecia, fatigue, swelling, stiff shoulders, coldness, numbness in the limbs, dullness and dullness in the skin Yes. Therefore, maintaining systemic blood circulation throughout the body is essential for maintaining normal functions and metabolism of living tissues and cells, and is important for maintaining healthy and quality of life (QOL). Generally known.

Attempts to search for active substances that improve blood flow have been studied in the past, and capsaicin, purple potato, dandelion and mugwort, saffron extract (Patent Document 1), perivisceral lipids of tiger snake (Patent Document 2), α-tocotrienol (patent document 3), cassis concentrate (patent document 4), koji extract (patent document 5), onion lactic acid fermented product (patent document 6) and the like have been proposed.

When these ingredients and extracts are used for food and drink applications, there is a risk of deterioration or degradation in the gastrointestinal tract, and depending on the individual, the effect may not always be clear, and the effectiveness is practically manifested. There were few things to get. Therefore, an effective material capable of promoting and / or improving the blood flow has been demanded.

The following is known about the camellia described later. That is, camellia has a history of being used as an ornamental horticultural plant since ancient times, and fats and oils collected from seeds are used as fuel oil, hair styling, high-grade edible oil, etc., and xylem is ashed to brew sake. The actual defatted rice bran has been used as a fertilizer for agricultural crops. The defatted cocoons contain saponins and tannins, and there are also proposals for processing them into insecticides (Patent Document 7), nematodes for agricultural and horticultural use (Patent Document 8), and the like. However, there is no example used to promote and / or improve blood flow by orally ingesting components contained in camellia seed defatted straw.

Japanese Patent Laid-Open No. 10-287576 JP 05-255110 A JP 2002-114678 A JP 2004-262878 A JP 2006-232763 A JP 2006-256969 A Japanese Patent No. 170071 JP-A-9-30916

In view of the present situation, the present inventors have developed a safe and stable new material for promoting and / or improving blood flow and providing a composition in an aspect that can be effectively used industrially. It was an issue.

In order to solve the above-mentioned problems, the present inventors have made extensive studies on materials for promoting and / or improving blood flow. As a result, surprisingly, camellia is extremely effective. Have been found to contain components that can significantly promote and / or improve blood flow, and can be effectively used in the fields of food and drink, pharmaceuticals, quasi-drugs, and feeds. It came to do.

That is, according to the present invention, there is provided an agent for improving blood flow promotion, comprising as an active ingredient an aqueous component of camellia (Camellia japonica) fruit and / or seed defatted koji belonging to the camellia family Camellia. Provided. The aqueous component is preferably an extract obtained by extracting a defatted product of Camellia japonica fruits and / or seeds with water and / or a lower alcohol.

Preferably, the aqueous component contains saponins, among which Camellia saponins A1, Camellia saponins A2, Camellia saponins B1, Camellia saponins (Camellia saponins, Camellia saponins) More preferred is C1 and / or Camellia saponin C2.

Moreover, according to this invention, the oral composition characterized by including the said blood-flow promotion improvement agent is provided. The oral composition is preferably a food or drink.

The aqueous component extracted from the defatted camellia camellia (Camellia japonica) seeds according to the present invention is excellent in quality stability and promotes and / or improves blood flow, thereby causing Raynosis, arteriosclerosis, Purger's disease, Hypertension, cerebral thrombus, cerebral infarction, myocardial infarction, hyperemia, congestion, bleeding, anemia, dementia, decreased immunity, alopecia, malaise, fatigue, muscle pain, tired eyes, swelling, stiff shoulders, back pain, itchy skin , Bears, dullness, moistening, frostbite, wrinkles, reduced skin elasticity, effects of preventing and / or improving symptoms caused by blood circulation disorders such as periodontal disease, and hair growth, hair growth, hair growth, nourishing tonic It has effects such as beautiful skin. Such an effect is remarkably expressed by orally ingesting or administering a blood flow promotion improving agent comprising the aqueous component as an active ingredient. Therefore, according to the present invention, an oral composition comprising the aqueous component as an active ingredient is provided, and food and drink, pharmaceuticals, and quasi drugs for preventing and / or improving symptoms caused by blood circulation disorders It can be used effectively as a product or feed.

The present invention is described in detail below. First, the blood flow promotion-improving agent of the present invention has a function of promoting and / or improving blood flow in humans and animals, and camellia belonging to the genus Camellia belonging to the family Camellia (Theaceae). It is characterized by containing an aqueous component of corn and / or seeds as an active ingredient.

As the plant belonging to the camellia genus, generally, the camellia camellia belonging to the camellia section, such as Camellia japonica, the tea belonging to the tea section (C. sinensis), the sasanqua belonging to the sasanqua section, C. sasanqua, etc. (C. granthamiana) and the like, and the long-tailed sasanqua (C. salticifolia) and the like, the Hime Sazanka (C. lutchuensis) and the like are known. It is possible to use. Examples of this are C. japonica var. Japonica, C. japonica subsp. Rusticana, C. japonica var. Macrocarpa, C. japonich. Hong Konggenesis, C. reticulata, C. salenensis, Pitaldi var. pitaldi, and C. partidi var. yunnica C, p. Japanese camellia (same kind as Japanese camellia), wild tea flower (same kind as Japanese camellia), yak Matsubaki can be mentioned (apple camellia and the like) and the like. What is necessary is just to utilize suitably these camellia which are growing naturally in the Japanese archipelago, the Korean peninsula, the Shandong peninsula of China, etc. In addition, in this invention, it is good to use a camellia camellia, a snowy camellia, an apple camellia, a Hozan camellia, a Japanese camellia, a mountain tea flower, or a Japanese camellia.

In the present invention, the above camellia nuts and / or seeds are subjected to a compression treatment, a supercritical extraction treatment using a hydrophobic organic solvent such as hexane or heptane, or a liquefied gas such as liquefied carbon dioxide or liquefied propane. Desirably, a defatted product, which is a residue obtained by extracting oil by a method, is used as a raw material for collecting the aqueous component. Here, the camellia seeds and / or seeds may be either early-ripening seeds or mature seeds, and these seeds may be used. From the viewpoint of the yield of the defatted product and the active ingredient, mature seeds or seeds thereof may be used. desirable. More preferably seeds are used. In the present invention, it is preferable to use seeds obtained from mature fruits dried for about 1 to 2 weeks in the sun.

The aqueous component of the defatted lees can be produced by any method, but it is preferable to extract it with water and / or lower alcohol. The lower alcohol has a tendency to extract the oily substance in the defatted soot as the carbon number of the lower alcohol increases. Therefore, those having a carbon number of up to about 5 are desirable, such as methanol, ethanol, normal propanol, isopropanol, normal butanol, isopropanol. Examples include butanol. When using a lower alcohol having a large carbon number, it is preferable to increase the water content in order to suppress the extraction of oily components in the defatted soot. For example, the water content in the case of propanol is about 20% by mass to about 50% by mass, and the water content in the case of butanol is about 40% by mass to about 70% by mass. Desirable extraction solvents are water, methanol and ethanol, and water-containing alcohols thereof (water content: 0 to 100% by mass).

In order to extract the defatted soot, the extraction solvent is added in an amount of about 1 to about 30 times by mass with respect to 1 part by weight of the defatted soot, and at about normal temperature or about 1 to 5 atm. After stirring and mixing for 10 minutes to about 3 hours as necessary, the mixture is cooled to room temperature and filtered, and the filtrate is concentrated and dried by an appropriate means such as drying under reduced pressure, spray drying or freeze drying. The dried product may be appropriately pulverized. In this way, a pale yellow to yellow-red solid that is an aqueous component of the defatted soot according to the present invention can be obtained. The extraction method is preferably performed by repeatedly extracting the extraction residue once extracted, or under a pressure of 1 to 3 atmospheres at about 100 ° C. to about 130 ° C. This increases the yield of the aqueous component according to the present invention. This aqueous component includes saponins, tannins and the like.

As a saponin contained in the aqueous component, 3β- [2-O-β-D-galactopyranosyl-3-O- (2-O-β-D-glucopyranosyl-α-L-arabinopyranosyl)- β-D-glucopyranuronosyloxy] oleana-12-ene-16α, 22α, 28-triol 22-[(Z) -2-methyl-2-butenoate] Camellia saponin A1, 3β- [2-O-β-D-galactopyranosyl-3-O- (2-O-β-D-glucopyranosyl-α-L-arabinopyranosyl) -β-D-glucopyranuronosyloxy ) Oleana-12-ene-16α, 22α, 28-triol 22-[(E) -2-methyl-2-butenoate] Camellia saponin A2, 3β- [2 O-β-D-galactopyranosyl-3-O- (2-O-β-D-glucopyranosyl-α-L-arabinopyranosyl) -β-D-glucopyranuronosyloxy) -16α , 28-dihydroxy-22α-[[(Z) -2-methyl-2-ptenoyl] oxy] oleana-12-en-23-al, Camellia saponin B1, 3β-[[2-O-β -D-galactopyranosyl-3-O- (2-O-β-D-glucopyranosyl-α-L-arabinopyranosyl) -β-D-glucopyranuronosyl) oxy] -16α, 28 Camellia saponin B2, 3β- [2 which is -dihydroxy-22α-[[((E) -2-methyl-2-butenoyl] oxy] oleana-12-en-23-al O-β-D-galactopyranosyl-3-O- (2-O-β-D-glucopyranosyl-α-L-arabinopyranosyl) -β-D-glucopyranuronosyloxy] oleana Camellia saponin C1, which is 12-ene-16α, 22α, 23,28-tetraol 22-[(Z) -2-methyl-2-butenoate], and 3β- [2-O-β-D -Galactopyranosyl-3-O- (2-O-β-D-glucopyranosyl-α-L-arabinopyranosyl) -β-D-glucopyranuronosyloxy] oleana-12-ene-16α , 22α, 23,28-tetraol 22-[(E) -2-methyl-2-butenoate], such as Camellia saponin C2, and the like. Ponin is specifically contained in camellia.

In the blood flow promotion improving agent of the present invention, the aqueous component as an active ingredient is in a solid, paste, or liquid form, which may be used as it is as a blood flow promotion improving agent. It is also possible to prepare a composition by using a conventional method in combination with known additives for uses in which the blood flow promoting agent is used. Here, known additives are preferably those commonly used for ingestion, for example, excipients, binders, disintegrants, lubricants, wetting agents, fluidizing agents, preservatives, surfactants. , Stabilizers, diluents, solubilizers, tonicity agents, bactericides, preservatives, corrigents, flavoring agents, coloring agents, flavoring agents, and other additive substances such as known ingredients having a blood flow improving effect can be used. You may use the containing material together.

In addition to the above-mentioned components and materials known to improve blood flow, black vinegar, glucosamine salt or glucosamine derivative, plum extract, ginkgo biloba extract, hesperidin, citrulline, ginger, egg white peptide, noripeptide, cow, pig or Examples thereof include fish-derived collagen peptides and γ-aminobutyric acid (GABA). In addition, this invention is not limited at all by these illustrations.

In the present invention, the aforementioned blood flow promoting and improving agent can be used as it is in various forms of foods and drinks, pharmaceuticals, quasi-drugs, feeds, and other industrial fields. It can utilize also in the aspect used as a part of. In particular, an oral composition for promoting and / or improving blood flow is preferred, and the most preferred embodiment of this oral composition is a food or drink. This example will be described below, but the present invention is not limited thereby.

When the blood flow improving agent of the present invention is used as an oral composition, it can be made into oral preparations such as granules, tablets, capsules, and liquids. The content of the aqueous component in such a pharmaceutical composition is difficult to define uniformly depending on the type and content of the combined raw materials, but is generally about 0.01% to 90% by mass, more preferably about 0.1% by mass. To about 70% by weight. When the content is less than about 0.01% by mass, the desired effect of the present invention is not recognized. When the content exceeds about 90% by mass, it is difficult to prepare a practical pharmaceutical composition. The blood flow-improving agent of the present invention is preferably used in such a manner that it is taken or administered orally. A suitable amount of the blood flow-improving agent of the present invention when taken or administered orally is about 10 mg to about 1,000 mg, preferably about 30 mg per day for a human adult, based on the aqueous component contained in the agent. To about 500 mg, more desirably from about 50 mg to about 300 mg.

The blood flow promotion-improving agent of the present invention can be used as a product in various forms of foods and drinks, pharmaceuticals, feeds, and other industrial fields, or it can be used in a form that is a part of a blended raw material of such products. be able to. For practical applications, food and drink are good.

Specific examples of food and drink include beverages such as vegetable juice, fruit juice drinks, soft drinks, tea, instant noodles, soup, jelly, pudding, yogurt, cake premix products, confectionery, sprinkles, miso, soy sauce, sauce, dressing , Mayonnaise, vegetable cream, seasonings such as grilled meat sauce and noodle soup, noodles, udon, soba noodles, spaghetti, processed meat and fish products such as ham and sausage, hamburger, croquette, sprinkle, boiled, jam, milk, cream, Various processed foods such as butter, spread and cheese, powdered, solid or liquid dairy products, margarine, bread, cake, cookies, chocolate, candy, gummi, gum, etc., powder, granules, pills , Tablet, soft capsule, hard capsule, paste or liquid dietary supplement, food for specified health use, Potential food, mention may be made of health food products, the concentrated liquid diet and dysphagia for food diet and the like.

In addition, in the food / beverage products of this invention, this contains the aqueous component of the camellia (Camellia japonica) fruit and / or seed which belong to the camellia genus (Camelia) of the Camellia family (Theaceae), the blood flow It can be set as the aspect which attached | subjected at least 1 display among the things for improving and / or improving.

In order to produce these foods and drinks, the blood flow promotion improving agent of the present invention and known raw materials may be used, or a part of the known raw materials may be replaced with the above blood flow promotion improving agent and produced by conventional methods. . For example, the blood flow promotion improving agent of the present invention may be prepared by adding glucose (dextrose), dextrin, lactose, starch or processed product thereof, excipients such as cellulose powder, vitamins, minerals, fats and oils of animals and plants, and seafood, as necessary. Proteins (including proteins from plants and animals, including hydrolysates thereof), carbohydrates, pigments, fragrances, antioxidants, surfactants, other edible additives, powders and extracts containing various nutritional functional ingredients Mixed with edible ingredients such as powders, granules, pellets, tablets, etc., processed into ordinary processed foods of the above examples by conventional methods, mixed liquids such as gelatin, sodium alginate, Suitable for use as a dietary supplement or health food by coating with a coating agent such as carboxymethylcellulose and forming into capsules or processing into beverages (drinks) A. In particular, tablets, capsules and drinks are desirable.

The ratio of the blood flow promotion improving agent of the present invention to be blended in such a food or drink is the form of the food or drink, the aqueous component in the blood flow promotion improving agent of the present invention (the camellia camellia camellia and / or seed aqueous). Component), the content of the aqueous component in the food or drink is about 0.01% by weight to about 90% by weight, although it is difficult to uniformly define the content of the other ingredients, the type of ingredients, the amount of the ingredients, and the amount of the ingredients. The prescription is designed by appropriately combining the blood flow promoting / improving agent of the present invention with other known ingredients for producing foods and drinks so as to be more preferably about 1% by mass to about 50% by mass, and the purpose is according to a conventional method. What is necessary is just to prepare food-drinks. In foods and beverages in which the content of the aqueous component is less than about 0.01% by mass, a large amount of the food and beverages must be ingested in order to expect the desired effect of the aqueous component, while the amount of the aqueous component If it exceeds about 90% by mass, it may be difficult to produce a practical food or drink. In the case of a human adult, the food / beverage product of the present invention can be arbitrarily selected so that the daily intake of the aqueous component is about 10 mg to about 1,000 mg, desirably about 30 mg to about 500 mg, more desirably about 50 mg to about 300 mg. This method can be taken into the body at the same time as, for example, or before or after meal intake, by oral intake, tube administration, or the like.

The pharmaceuticals using the blood flow promotion improving agent of the present invention are prepared by appropriately adding known excipients and additives that do not contradict the gist of the present invention to the above blood flow promotion improving agent and processing them by conventional methods. Preparations such as powders, granules, powders, and liquids. Oral or enteral administration is applied to promote and / or improve blood flow or to prevent or treat the above symptoms. The blending amount of the blood flow promotion improving agent of the present invention is difficult to set uniformly depending on the form and the type, form, usage, dosage and the like of the pharmaceutical preparation, but the content of the aqueous component is generally 0.01% by mass to 50% by mass. %. The amount of intake when orally administered is not particularly limited. For example, based on the aqueous component, about 0.1 mg to about 1,000 mg, preferably about 1 mg to about 500 mg per day for a human adult, More desirably, it is about 10 mg to about 300 mg.

Moreover, in order to apply the blood flow promotion improving agent of the present invention to pet food and livestock feed, it is blended into various known feeds and drinking water, as well as known raw materials and additives, as in the case of the food and drink. At the same time, it can be processed into preparations such as tablets, granules, and capsules. In these cases, the blending amount of the blood flow promotion improving agent of the present invention is about 0.01% by mass to about 90% by mass, more desirably about 1% by mass to about 50% by mass as the content of the aqueous component, The standard of daily intake is about 0.1 mg to about 100 mg, more desirably about 0.5 mg to about 50 mg per body weight (kg) of the applied animal, based on the aqueous component.

Production Example 1
After coarsely crushing dried seeds of C. japonica var. Japonica from Goto, Nagasaki Prefecture, steaming and then pressing to obtain a press knead separated from the compressed oil, followed by adding normal hexane to the press koji and extracting by a conventional method After processing, the extract was separated and the extract was collected. The extract was washed with normal hexane to remove the oil, and a defatted material was collected. Water (300 mL) was added to 100 g of the defatted material, heated to 85 ° C. under normal pressure and stirred appropriately for 1 hour, cooled to room temperature, and filtered to separate the filtrate. 200 mL of water was again added to the filtration residue, and the mixture was heated, stirred and cooled in the same manner, and then filtered to collect a filtrate. Both filtrates were combined, concentrated under reduced pressure, freeze-dried and pulverized to obtain 16.4 g of a powder containing the aqueous component according to the present invention (referred to as sample 1). When this powder was hydrolyzed and analyzed by HPLC, it contained 16.8% sapogenin, which is an aglycon of saponin, and 2.1% kaempferol, which is a kind of flavonol.

Production Example 2
The dried seeds of Yakushima-made Yakushima pine (C. japonica var. Macrocarpa) were defatted by the method described in Production Example 1 and the defatted material was collected. 300 mL of water was added to 100 g of this defatted material, heated at 120 ° C. under a pressure of 2 atm for 25 minutes, cooled to room temperature, and filtered to separate the filtrate. 200 mL of water was again added to the filtration residue, and the mixture was heated, stirred and cooled in the same manner, and then filtered to collect a filtrate. Both filtrates were combined, concentrated under reduced pressure, lyophilized and pulverized to obtain 16.9 g of a powder containing the aqueous component according to the present invention (referred to as sample 2). The powder was hydrolyzed in the same manner as in Production Example 1 and analyzed by HPLC. As a result, the sapogenin content was 15.1% and the kaempferol content was 2.5%.

Production Example 3
250 g of water-containing ethanol (water content 50%) was added to 100 g of the defatted product obtained by the method described in Production Example 1, and the mixture was heated to reflux at 80 ° C. for 1 hour, cooled to room temperature, and filtered to separate the filtrate. To this filtration residue, 200 mL of hydrous ethanol (water content 50%) was added again and heated in the same manner. After cooling, the filtrate was collected by filtration. Both filtrates were combined, concentrated under reduced pressure, freeze-dried and pulverized to obtain 12.3 g of a powder containing the aqueous component according to the present invention (referred to as sample 3). The powder was hydrolyzed in the same manner as in Production Example 1 and analyzed by HPLC. As a result, the sapogenin content was 12.5% and the kaempferol content was 2.7%.

Production Example 4
Ethanol (purity 99.5%) 200 mL was added to 100 g of the defatted product obtained by the method described in Production Example 2, and the mixture was heated to reflux at 80 ° C. for 1 hour, cooled to room temperature, and filtered to separate the filtrate. 200 mL of ethanol (purity 99.5%) was again added to the filtration residue and heated in the same manner. After cooling, the filtrate was collected by filtration. Both filtrates were combined, concentrated under reduced pressure, lyophilized and pulverized to obtain 4.3 g of a powder (referred to as sample 4) containing an aqueous component according to the present invention. The powder was hydrolyzed in the same manner as in Production Example 1 and analyzed by HPLC. As a result, the sapogenin content was 14.0% and the kaempferol content was 2.5%.

Production Example 5
In Production Example 1, except that the dried seed was replaced with immature fruit (whole seed-containing seed), the same treatment was performed to obtain a defatted koji, and then 12.8 g of a powder containing an aqueous component (referred to as sample 5). Got. The powder was hydrolyzed in the same manner as in Production Example 1 and analyzed by HPLC. As a result, the sapogenin content was 13.2% and the kaempferol content was 2.4%.

Production Example 6
Water (300 mL) is added to 100 g of dried leaves of Camellia sinensis, a plant belonging to the camellia family, heated to 85 ° C. under normal pressure, stirred for 20 minutes, cooled to room temperature, filtered, and the filtrate was filtered. separated. To this filtration residue, 200 mL of water was added again and heated in the same manner. After stirring and cooling, the filtrate was collected by filtration. Both filtrates were combined and concentrated under reduced pressure. The concentrated solution was subjected to column chromatography packed with synthetic adsorbent Diaion HP-20 (manufactured by Mitsubishi Chemical Corporation). After washing by passing 500 mL of water, 500 mL of water-containing ethanol (water content 30%) was passed through to collect a tea catechin-containing solution soluble in the water-containing ethanol. This solution was concentrated under reduced pressure, freeze-dried and pulverized to obtain 2.5 g of powder (referred to as Comparative Sample 1). As a result of HPLC analysis of the powder, the content of catechins was 91.8%.

Test Example 1: 36 males with 44 to 65 years old who had consented to participate in the blood flow increasing effect test were divided into 6 groups per group by double blind method. A test was conducted. First, the subject entered a room of constant temperature and humidity controlled at a temperature of 24 ± 2 ° C. and a humidity of 50 ± 10%, and was allowed to stand quietly for 10 minutes. Ten minutes later, the blood flow in the back of the hand and scalp before taking the test sample was measured using a laser Doppler (Periscan, PeriScan PIMII). Next, in the control group (placebo group), hard capsules (made of gelatin; the same applies hereinafter) filled with dextrin so that the subject cannot distinguish by color, and in the other groups, hard capsules colored as described above. Each sample was ingested with 100 mL of water, and after 30 minutes and 60 minutes, blood flow in the back of the hand and scalp was measured again in the same manner as described above.

The results are shown in Tables 1 and 2. In the table, the numerical values are expressed as average values ± standard deviation (n = 6, ANOVA analysis) as relative values when the value before taking the placebo and the test substance is 100. From the data in Tables 1 and 2, no significant changes were observed in the blood flow of the back of the hand and scalp of subjects who took placebo, and the group that took Comparative Sample 1 showed significant changes in blood flow after 30 minutes of ingestion. Although no difference was observed, the blood flow values of the back of the hand and scalp were significantly higher at 60 minutes after ingestion compared to the placebo group. Moreover, in the group which ingested the samples 1-5, the value of the blood flow volume of the back of the hand and the scalp was significantly higher at both 30 minutes and 60 minutes after the placebo. Thereby, it became clear by ingesting the sample which concerns on this invention that a blood flow rate increases. The effect was stronger than that of Comparative Sample 1.

Test Example 2: Components having an effect of improving blood flow promotion In order to elucidate a substantially effective ingredient having an action of improving blood flow, the powder of Sample 1 obtained in Production Example 1 was subjected to high performance liquid chromatography under the following conditions. (HPLC) was subjected to fractionation treatment. Apparatus: LC-10A series manufactured by Shimadzu Corporation, column: COSMOSIL5C18-MS-II (10 × 250 mm) manufactured by Nacalai Tesque, eluent: A solution is 0.1% acetic acid, B solution is 0.1 % Acetic acid and 40% acetonitrile, gradient analysis of liquid A and liquid B, flow rate: 2 mL / min, UV detection at 210 nm. Sample 1 was dissolved in 0.1% acetic acid and 40% acetonitrile solution and filtered through a 0.45 μm membrane filter. The solution was subjected to HPLC, and repeated fractionation according to the fraction from which saponin was eluted to purify the Tsubakisponins specifically contained in Camellia. Moreover, fractionation was also performed except for the portion where the saponin was eluted. These were concentrated under reduced pressure and freeze-dried to obtain a powder of Tsubakisaponins (referred to as sample 6) and a powder of non-Tsubakisaponins (referred to as sample 7). Sample 6 contained camelia saponins A1, A2, B1, B2, C1 and C2.

The following test was performed about the influence which these samples have on the blood flow rate. A 6-week-old ICR male mouse (purchased from Nippon Claire Co., Ltd.) under the control of temperature and humidity, with a 12-hour light / dark cycle, food (Nippon Claire Co., Ltd., CE-2) and drinking water are ingested freely And pre-bred for 1 week. Thereafter, 10 mice per group were grouped into a total of 4 groups, each administered with the control group, sample 1, sample 6 and sample 7, each subjected to ether anesthesia, and each mouse before administration of each sample The blood flow at the sole of the foot was measured in the same manner as in Test Example 1. Next, distilled water was administered to the control group, and each sample was orally administered at 50 mg / kg body weight to the other groups, and the blood flow after 30 minutes and 60 minutes was measured in the same manner.

The results are shown in Table 3. In the same table, the numerical values are expressed as average values ± standard deviation (n = 6, ANOVA analysis) as relative values when the value before taking the placebo and each test substance is 100. From the data in Table 3, the control group and the group to which sample 7 was administered did not show a significant change in blood flow, but in the group to which sample 1 and sample 6 were administered, 30 minutes and 60 minutes later At both times, blood flow was significantly higher than the control group. Thereby, it became clear that blood flow volume increases by ingestion of sample 1 and sample 6 concerning the present invention. In addition, the effect of increasing blood flow was not observed in sample 7, and the effect of increasing blood flow was observed in sample 6. Therefore, the effect of increasing blood flow was due to Tsubakisponins specifically contained in camellia. It was strongly suggested that there was.

Test Example 3 36 women who complained of coldness from 25 to 40 years old who agreed to participate in the blood flow improvement test were divided into 6 groups per group, double blind. The test was conducted by the inspection method. First, the subject entered a room of constant temperature and humidity controlled at a temperature of 24 ± 2 ° C. and a humidity of 50 ± 10%, and was allowed to stand quietly for 10 minutes. Ten minutes later, the blood flow of the right hand was measured in the same manner as in Test Example 1, and then a cold water load was applied to the subject's right hand in a wash basin with a water temperature of 14 ° C. for 5 minutes. The blood flow of the right hand before ingestion was measured in the same manner as described above. Next, in the control group, the hard capsules colored so that the subject could not discriminate were filled with dextrin, and in the other groups, the same colored hard capsules filled with each sample were taken with 100 mL of water. After 10 minutes and 30 minutes, the blood flow of the right hand was measured again in the same manner as described above.

The results are shown in Table 4. In the same table, the numerical values are expressed as average values ± standard deviation (n = 6, ANOVA analysis) as relative values when the value before taking the placebo and each test substance is 100. From the data of Table 4, it became clear that the aqueous component of the defatted camellia seeds according to the present invention quickly restores blood flow.

Test example 4
Twenty subjects aged 40 to 65 years were ingested orally for 6 months with placebo (dextrin) filled in hard capsules and sample 1 with an internal volume of 300 mg / day to evaluate the effect on hair growth rate and hair thickness did. As a result, the hair growth rate per day was 0.408 mm in the group that ingested Sample 1 compared to 0.408 mm in the placebo-intake group. In addition, the hair diameter was 0.099 mm in the placebo group, while the group ingesting Sample 1 was 0.112 mm. Both the hair growth rate and the hair diameter were significantly increased by oral intake of Sample 1, and hair growth and / or hair growth effects were also observed.

Prototype example 1
Any one of Samples 1 to 5 as the blood flow promotion improving agent of the present invention was subjected to a capsule filling machine, and a gelatin-coated hard capsule preparation having an inner volume of 200 mg per grain was prepared by a conventional method. The other samples were processed in the same manner to produce five types of gelatin-coated hard capsule formulations. These capsule preparations can be used as dietary supplements, medicines and the like that can be taken orally.

Prototype example 2
Sample 2: 150 parts (mass basis; the same applies hereinafter), beeswax: 40 parts and evening primrose oil (manufactured by Efamol Co., Ltd.): 80 parts as a blood flow promoting agent of the present invention are heated and mixed to about 50 ° C. to be homogeneous. After that, it was subjected to a capsule filling machine, and a gelatin-coated soft capsule preparation having an inner volume of 200 mg per grain was produced by a conventional method. This capsule preparation can be used as a dietary supplement that can be taken orally.

Prototype example 3
Sample 30:30 as a blood flow promotion improving agent of the present invention, green tea extract (manufactured by BN Co., Ltd.): 0.5 part, corn starch (manufactured by Nippon Corn Starch Co., Ltd.): 105 parts, tricalcium phosphate ( Yoneyama Chemical Co., Ltd.): 50 parts and Riboflavin (DSM Nutrition Japan Co., Ltd.): 7 parts were charged into a mixer and mixed with stirring for 10 minutes. This mixture was subjected to a direct compression tableting machine to prepare uncoated tablets having a diameter of 7 mm, a height of 4 mm, and a mass of 150 mg / piece, and then a shellac film was formed by the coating machine to produce a tablet-shaped food.

Prototype example 4
Sample 100 as a blood flow promotion improving agent of the present invention: 200 mg was added to 100 mL of a commercially available nutrition drink and mixed well to prepare a beverage. Even if this was stored in a refrigerator for 1 year, no abnormalities or discomfort was observed in the appearance and flavor. In addition, this product can be used for blood flow promotion and / or improvement, cooling property improvement, hair growth and the like.

Prototype example 5
In the instant noodle manufacturing process, 300 mg of Sample 1 as a blood flow promotion improving agent of the present invention was added to a known raw material to make an instant noodle. Even when it was stored at room temperature for 6 months, no abnormality or discomfort was observed in appearance and flavor. In addition, this product can be used for blood flow promotion and / or improvement.

According to the present invention, a blood flow promoting and improving agent comprising an aqueous component of camellia (Camellia japonica) fruit and / or seed defatted lees as an active ingredient belongs to the genus Camellia belonging to the camellia family. Has the effect of promoting and / or improving blood flow, and can be effectively used for food and drink, pharmaceuticals, quasi-drugs, feeds, etc. to promote and / or improve blood flow and improve symptoms .

Claims (6)

An agent for improving blood flow promotion for oral use (excluding food) comprising an aqueous component of camellia (Camellia japonica) seeds according to (a) belonging to the camellia family Camellia genus as an active ingredient.
(A) Yabu camellia, snowy camellia, apple camellia, Hozan camellia, Japanese camellia, wild tea flower or Yakushi camellia.   2. The blood flow promoting agent according to claim 1, wherein the aqueous component is an extract obtained by subjecting a camellia japonica seed defatted product to an extraction treatment with water and / or a lower alcohol.   The blood flow promotion improving agent according to claim 1 or 2, wherein the aqueous component contains saponins.   The saponins are Camellia saponin A1, Camellia saponin A2, Camellia saponin B1, Camellia saponin B2 and Camellia saponin Cellias / cellia saponin Celliaspon. 3. The blood flow promoting agent according to 3. Excluding Ri Na contain blood flow promoting improving agent according to claim 1, the oral composition for promoting and / or improve blood flow in the symptoms caused by hematogenous disorder (Food .) The oral composition according to claim 5, wherein the symptom is thin hair or coldness.